mFOLFIRINOX Plus Anlotinib and Sintilimab for Advanced Pancreatic Cancer
mFOLFIRINOX Plus Anlotinib and Sintilimab for Advanced Pancreatic Cancer
Recruiting · NCT06761027 · Registry updated 2025-01-07Clinical trials
Swipe the table sideways for more columns.
| Trial | Conditions | Status | Phase | Updated | More info | NCT ID |
|---|---|---|---|---|---|---|
| mFOLFIRINOX Plus Anlotinib and Sintilimab for Advanced Pancreatic Cancer | Digestive System Diseases, Digestive System Neoplasms, Neoplasms by Site, endocrine system disorder, malignant endocrine neoplasm, neoplasm, pancreas disorder, pancreatic neoplasm | Recruiting | Phase 1 / Phase 2 | 2025-01-07 | NCT06761027 |
1 results · Page 1 of 1
Organizations
Swipe the table sideways for more columns.
| Organizations | Linked trials |
|---|---|
| Fujian Provincial Hospital | 45 |
4 results · Page 1 of 1
Research sites
Swipe the table sideways for more columns.
| Research sites | City | Country | Linked trials |
|---|---|---|---|
| First Affiliated Hospital of Fujian Medical University | Fuzhou | China | 6 |
| Fujian Provincial Hospital | Fuzhou | China | 14 |
| Mengchao Hepatobiliary Hospital of Fujian Medical University | Fuzhou | China | 9 |
| Zhangzhou Affiliated Hospital of Fujian Medical University | Zhangzhou | China | 2 |